Equities

Zhejiang Huahai Pharmaceutical Co Ltd

600521:SHH

Zhejiang Huahai Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)17.34
  • Today's Change0.06 / 0.35%
  • Shares traded8.15m
  • 1 Year change-6.02%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ZHEJIANGHUAHAIPHARMACEUTICALCO., LTD is a China-based company, principally engaged in the manufacture and distribution of active pharmaceutical ingredients (APIs), intermediates and preparations. The Company's main products are classified as -pril series, -sartan series and preparations, including irbesartan tablets, paroxetine hydrochloride tablets, risperidone tablets, fosinopril sodium tablets, as well as irbesartan and hydrochlorothinzide tablets, among others. The Company also provides related technical support services. The Company distributes its products in domestic and overseas markets.

  • Revenue in CNY (TTM)8.75bn
  • Net income in CNY928.37m
  • Incorporated2001
  • Employees8.22k
  • Location
    Zhejiang Huahai Pharmaceutical Co LtdXunqiao, Linhai CityTAIZHOU 317024ChinaCHN
  • Phone+86 57 685991096
  • Fax+86 57 685016010
  • Websitehttps://www.huahaipharm.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
China Resources Dubl-Crne Phrmctl Co Ltd10.32bn1.38bn22.00bn12.27k15.771.88--2.131.341.3410.0711.240.67812.855.82841,054.608.878.5811.6711.2154.2558.1913.0811.982.15--0.024935.916.204.4412.966.6021.46-1.63
Xiamen Amoytop Biotech Co Ltd2.23bn600.08m22.23bn1.96k37.0511.09--9.991.481.485.474.931.040.85416.701,135,877.0028.0917.9632.7221.0293.1790.4826.9519.173.22--0.003726.9537.5536.1993.52103.2881.61--
Shanghai Junshi Biosciences Co Ltd1.63bn-2.02bn23.08bn2.57k--3.85--14.18-2.06-2.061.666.970.13481.054.11634,034.10-18.18-18.87-23.17-23.1164.0569.13-134.86-88.411.91-215.800.3018--3.38248.394.38--8.36--
Joincare Pharmaceutical Group Ind. Co.16.43bn1.42bn23.28bn14.37k16.251.64--1.420.76760.76768.867.630.45222.365.571,143,551.007.988.4616.5118.8461.2362.7217.6417.002.11--0.224728.86-2.908.24-3.9915.5811.532.38
Kangmei Pharmaceutical Co Ltd4.93bn160.40m25.65bn4.41k159.073.62--5.200.01160.01160.35770.51170.341.402.431,118,464.001.12-17.601.69-32.2422.71-72.783.28-101.190.8746--0.0465--16.60-22.17103.81-22.83-53.51--
Zhejiang Huahai Pharmaceutical Co., Ltd.8.75bn928.37m25.71bn8.22k27.133.01--2.940.63910.63916.025.760.45111.083.461,064,162.004.765.676.908.0759.4460.5210.5511.610.84515.480.504733.550.519910.28-28.8850.517.21--
Shanghai Allist Pharmaceuticals Co Ltd2.48bn915.35m26.15bn1.04k28.576.05--10.532.032.035.529.600.60913.1610.512,379,802.0022.440.640524.190.693394.4896.4236.842.548.22--0.0004211.88155.14237.34393.54--13.53--
Bluestar Adisseo Co13.53bn327.58m26.55bn2.73k81.051.76--1.960.12220.12225.045.630.62864.677.334,947,799.001.525.281.856.9423.8130.312.428.761.044.300.132521.81-9.262.92-95.82-43.752.74-19.09
Gan & Lee Pharmaceuticals2.61bn386.85m29.17bn4.48k72.252.64--11.170.67160.67164.5218.380.2340.892610.97582,412.303.478.303.718.8372.2985.3914.8326.447.74--0.000613.6552.311.78177.37-18.301.50--
Autobio Diagnostics Co Ltd4.50bn1.30bn30.07bn5.54k22.933.39--6.692.242.247.7415.110.40662.084.27811,768.3011.8112.5914.5015.7964.7661.6229.0426.962.81--0.103546.400.045718.154.2816.7017.0311.32
Data as of May 31 2024. Currency figures normalised to Zhejiang Huahai Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

3.68%Per cent of shares held by top holders
HolderShares% Held
Essence Fund Co., Ltd.as of 31 Dec 20238.90m0.61%
Golden Trust Sinopac Fund Management Co., Ltd.as of 31 Dec 20238.64m0.59%
China Southern Asset Management Co., Ltd.as of 31 Dec 20237.44m0.51%
Zhong Ou Asset Management Co., Ltdas of 31 Dec 20237.41m0.51%
Rongtong Fund Management Co., Ltd.as of 31 Dec 20234.30m0.30%
The Vanguard Group, Inc.as of 09 May 20244.00m0.28%
Harvest Fund Management Co., Ltd.as of 31 Dec 20233.87m0.27%
Galaxy Asset Management Co., Ltd.as of 31 Dec 20233.53m0.24%
Guotai Asset Management Co., Ltd.as of 31 Dec 20233.06m0.21%
China Merchants Fund Management Co., Ltd.as of 31 Dec 20232.41m0.17%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.